UCLA‐0302038

Trial name or title	PCI‐P‐PCYC‐0211 Phase III randomized study of motexafin gadolinium and WBRT versus WBRT alone in patients with brain metastases secondary to non‐small cell lung cancer
Methods
Participants	1. histologically confirmed non‐small cell lung cancer 2. no liver metastases 3. no extracranial metastases to more than one organ 4. no leptomeningeal metastases
Interventions	WBRT versus WBRT and motexafin gadolinium
Outcomes	1. time to neurologic progression or death (with neurologic progression) 2. time to neurocognitive progression 3. time to loss of functional independence 4. time to all cause mortality
Starting date
Contact information
Notes

CNS = central nervous system KPS = Karnofsky performance status MRI = magnetic resonance imaging RSR 13 = efaproxiral WBRT = whole brain radiotherapy